» Articles » PMID: 23637316

Survival and Causes of Death in an Unselected and Complete Cohort of Norwegian Patients with Systemic Sclerosis

Overview
Journal J Rheumatol
Specialty Rheumatology
Date 2013 May 3
PMID 23637316
Citations 26
Authors
Affiliations
Soon will be listed here.
Abstract

Objective: To determine survival and causes of death in an unselected and complete cohort of Norwegian patients with systemic sclerosis (SSc) compared to the background population.

Methods: Multiple methods were used to identify every patient with SSc living in southeast Norway, with a denominator population of 2,707,012, between 1999 and 2009. All patients who met either the American College of Rheumatology criteria or the Medsger and LeRoy criteria for SSc were included. Every patient was matched for sex and age with 15 healthy controls drawn from the national population registry. Vital status at January 1, 2010, was provided for patients and controls by the national population registry. Causes of death were obtained from death certificates and by chart review.

Results: Forty-three (14%) of 312 patients with SSc died during the study period. The standardized mortality rate (SMR) was estimated to be 2.03 for the entire cohort and 5.33 for the subgroup with diffuse cutaneous (dc) SSc. The 5- and 10-year survival rates were 91% and 70%, respectively, for dcSSc and 98% and 93% for limited cutaneous (lc) SSc. Causes of death were related to SSc in 24/43 (56%) patients, mostly cardiopulmonary diseases (n = 13), including pulmonary hypertension (n = 8). Factors associated with fatal outcome included male sex, dcSSc, pulmonary hypertension, and interstitial lung disease.

Conclusion: Compared to the Norwegian background population, our cohort of 312 unselected patients with SSc had decreased survival. The survival rates observed were, however, better than those previously reported from SSc referral centers.

Citing Articles

A Multidisciplinary Approach as a Goal for the Management of Complications in Systemic Scleroderma: A Literature Review and Case Scenario.

Patrintasu D, Sarkozi H, Lupusor E, Vlangar I, Rotariu G, Renta I Diagnostics (Basel). 2023; 13(21).

PMID: 37958228 PMC: 10648338. DOI: 10.3390/diagnostics13213332.


Sex bias in immune response: it is time to include the sex variable in studies of autoimmune rheumatic diseases.

Sakkas L, Chikanza I Rheumatol Int. 2023; 44(2):203-209.

PMID: 37716925 DOI: 10.1007/s00296-023-05446-8.


Predictors of outcomes in mild pulmonary hypertension according to 2022 ESC/ERS Guidelines: the EVIDENCE-PAH UK study.

Karia N, Howard L, Johnson M, Kiely D, Lordan J, McCabe C Eur Heart J. 2023; 44(44):4678-4691.

PMID: 37619574 PMC: 10659956. DOI: 10.1093/eurheartj/ehad532.


Standardized mortality ratios in systemic sclerosis: a meta-analysis assessing overall and sex- and disease subtype-specific differences.

Lee Y, Song G Z Rheumatol. 2023; 83(Suppl 1):175-182.

PMID: 37597012 DOI: 10.1007/s00393-023-01401-x.


Viewpoint: a multidisciplinary approach to the assessment of patients with systemic sclerosis-associated interstitial lung disease.

Chatterjee S, Perelas A, Yadav R, Kirby D, Singh A Clin Rheumatol. 2022; 42(3):653-661.

PMID: 36271064 PMC: 9935731. DOI: 10.1007/s10067-022-06408-4.